Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

Leukemia

Volumn 26, Issue 11, 2012, Pages 2317-2325

  Comenzo, R L ^a   Reece, D ^b   Palladini, G ^c   Seldin, D ^d   Sanchorawala, V ^d   Landau, H ^e   Falk, R ^f   Wells, K ^g   Solomon, A ^g   Wechalekar, A ^h   ZonDer, J ⁱ   Dispenzieri, A ^j   Gertz, M ^j   Streicher, H ^k   Skinner, M ^d   Kyle, R A ^j   Merlini, G ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF PAVIA   (Italy)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ KARMANOS CANCER INSTITUTE   (United States)

^j MAYO CLINIC   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Amyloidosis; Clinical research; Clinical trials; Free light chains

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; CONSENSUS; DRUG DEVELOPMENT; HUMAN; INFORMATION PROCESSING; ORGAN INJURY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

AMYLOIDOSIS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84869081202     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.100     Document Type: Review

References (53)

1. Merlini G, Palladini G. Amyloidosis: Is a cure possible? Ann Oncol 2008; 19(Suppl 4): Iv63-iv66.
2. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817-1822.
3. Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med 2007; 356: 2413-2415. (Pubitemid 46883777)
4. Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143: 369-373.
5. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis. Amyloid 2005; 12: 120-126. (Pubitemid 40978721)
6. Wechalekar AD, Offer M, Gillmore JD, Hawkins PN, Lachmann HJ. Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nat Clin Pract Cardiovasc Med 2009; 6: 128-133.
7. Wechalekar A, Kastritis E, Merlini G, Hawkins PN, Dimopoulos MA, Russo P et al. European collaborative study of 153 patients with systemic AL amyloidosis with Mayo stage III disease. Haematologica 2011; 96(Suppl 1): S158.
8. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596. (Pubitemid 36951371)
9. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: Patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107: 3489-3491.
10. Merlini G, Westermark P. The systemic amyloidoses: Clearer unDerstanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159-178. (Pubitemid 38241361)
11. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: A review. Immunol Rev 2003; 194: 112-139. (Pubitemid 36886433)
12. Arbustini E, Morbini P, Verga L, Concardi M, Porcu E, Pilotto A et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 1997; 4: 157-170. (Pubitemid 127496648)
13. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen 3rd HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-4959.
14. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119: 1844-1847.
15. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94: 380-386.
16. Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111: 4700-4705.
17. Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of Cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 2012; 12: 49-58.
18. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84. (Pubitemid 36819341)
19. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorDers. Leukemia 2009; 23: 215-224.
20. Palladini G DA, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schö nland S et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010; 116: 1364.
21. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007; 376: 30-36. (Pubitemid 44880976)
22. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757. (Pubitemid 41095215)
23. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426-3430.
24. Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D et al. Assessment of disease severity and outcome in patients with systemic lightchain amyloidosis by the high-sensitivity troponin T assay. Blood 116: 2455-2461.
25. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047-2060. (Pubitemid 41377426)
26. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445. (Pubitemid 36605226)
27. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-1789. (Pubitemid 36638428)
28. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
29. Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010; 116: 2241-2244.
30. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-97.
31. Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood 118: 6610-6617.
32. Kyle RA, Greipp PR. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo. Blood 1978; 52: 818-827. (Pubitemid 9032653)
33. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998; 91: 3662-3670. (Pubitemid 28225733)
34. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328. (Pubitemid 41098849)
35. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: An updated consensus opinion. Amyloid 2010; 17: 48a.
36. Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: An observational cohort study. J Am Soc Echocardiogr 2010; 23: 643-652.
37. Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010; 116: 522-528.
38. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037.
39. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis unDergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887. (Pubitemid 39202301)
40. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85: 757-759.
41. Seldin DC, AnDerson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888-1893. (Pubitemid 39202302)
42. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 2001; 134(9 Part 1): 746-753. (Pubitemid 32402067)
43. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858. (Pubitemid 43726787)
44. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 2011; 118: 4346-4352.
45. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.
46. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007; 110: 3561-3563. (Pubitemid 350159622)
47. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007; 109: 492-496. (Pubitemid 46105943)
48. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465-470. (Pubitemid 46105939)
49. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457-464. (Pubitemid 46105938)
50. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study. Blood 2011; 118: 865-873.
51. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: Results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520-3526. (Pubitemid 39564422)
52. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Riskadapted autologous stem cell transplantation with adjuvant dexamethasone ±thalidomide for systemic light-chain amyloidosis: Results of a phase II trial. Br J Haematol 2007; 139: 224-233. (Pubitemid 47495869)
53. Landau H HH, Bello C, Hoover E, Jia X, Riedel ER, Nimer SD et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2010; 17: 80a.